Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANG005
MIFTS: 49

Anogenital Venereal Wart

Categories: Infectious diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anogenital Venereal Wart

About this section

MalaCards integrated aliases for Anogenital Venereal Wart:

Name: Anogenital Venereal Wart 12 15
Genital Warts 12 55 43 3
Condylomata Acuminata 44 73
Condyloma Acuminatum 12 76
Anogenital Human Papilloma Virus Infectious Disease 12
Genital Wart Virus Infectious Disease 12
Anogenital Warts 12
Venereal Wart 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Anogenital Venereal Wart

About this section
MedlinePlus : 43 Genital warts are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV). The warts usually appear as a small bump or group of bumps in the genital area. They are flesh-colored and can be flat or look bumpy like cauliflower. Some genital warts are so small you cannot see them. In women, the warts usually occur in or around the vagina, on the cervix, or around the anus. In men, genital warts are less common. They may have warts on the tip of the penis, around the anus, or on the scrotum, thigh, or groin. You can get genital warts during oral, vaginal, or anal sex with an infected partner. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. HPV vaccines may help prevent some of the HPV infections that cause genital warts. Your health care provider usually diagnoses genital warts by seeing them. The warts might disappear on their own. If not, your health care provider can treat or remove them. HPV stays in your body even after treatment, so warts can come back. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Anogenital Venereal Wart, also known as genital warts, is related to vulva cancer and papilloma, and has symptoms including anogenital warts, fever and pelvic pain. An important gene associated with Anogenital Venereal Wart is TLR7 (Toll Like Receptor 7), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Viral carcinogenesis. The drugs Imiquimod and Zinc have been mentioned in the context of this disorder. Affiliated tissues include skin of vagina, skin and cervix, and related phenotypes are Increased BBC3 mRNA expression and homeostasis/metabolism

CDC : 3 HPV is a very common virus; nearly 80 million people—about one in four—are currently infected in the United States. Learn how you can protect the children in your life from this cancer-causing virus.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, and throat, has material basis in human papillomaviruses (types 6 and 11), which are transmitted by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has symptom anogenital warts.

Wikipedia : 76 Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus... more...

Sources

Related Diseases for Anogenital Venereal Wart

About this section

Diseases related to Anogenital Venereal Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 vulva cancer 31.2 CDKN2A TP53
2 papilloma 29.3 CDKN2A TP53 UBE3A
3 buschke lowenstein tumor 11.6
4 septicemic plague 10.7 IFNB1 TLR7
5 balanoposthitis 10.6 CDKN2A GP6
6 cervix disease 10.5 CDKN2A GP6
7 squamous cell carcinoma 10.3
8 cervicitis 10.2
9 urethritis 10.2
10 vaginitis 10.2
11 cervical cancer 10.1
12 cervical carcinosarcoma 10.1 GP6 TP53
13 brain stem astrocytic neoplasm 10.0 CDKN2A TP53
14 keratinizing squamous cell carcinoma 10.0 CDKN2A TP53
15 spitz nevus 10.0 CDKN2A TP53
16 bladder carcinoma in situ 10.0 CDKN2A TP53
17 bartholin's gland benign neoplasm 10.0 CDKN2A TP53
18 vulva squamous cell carcinoma 10.0 CDKN2A TP53
19 spinal cord astrocytoma 10.0 IFNB1 TP53
20 thyroid lymphoma 10.0 CDKN2A TP53
21 nasal cavity adenocarcinoma 10.0 CDKN2A TP53
22 bone squamous cell carcinoma 10.0 CDKN2A TP53
23 scrotal carcinoma 10.0 CDKN2A TP53
24 anal squamous cell carcinoma 10.0 CDKN2A TP53
25 cerebral primitive neuroectodermal tumor 10.0 IFNB1 TP53
26 glycogen-rich clear cell breast carcinoma 10.0 CDKN2A TP53
27 gastric adenosquamous carcinoma 10.0 CDKN2A TP53
28 oral leukoplakia 10.0 CDKN2A TP53
29 megaesophagus 9.9 CDKN2A TP53
30 schneiderian carcinoma 9.9 CDKN2A TP53
31 molluscum contagiosum 9.9
32 meningeal melanomatosis 9.9 CDKN2A TP53
33 dedifferentiated liposarcoma 9.9 CDKN2A TP53
34 endocervical adenocarcinoma 9.9 CDKN2A TP53
35 cervix small cell carcinoma 9.9 CDKN2A TP53
36 necrotizing sialometaplasia 9.9 CDKN2A TP53
37 basaloid squamous cell carcinoma 9.9 CDKN2A TP53
38 biliary tract neoplasm 9.9 CDKN2A TP53
39 inverted papilloma 9.9 CDKN2A TP53
40 optic nerve neoplasm 9.9 CDKN2A TP53
41 recessive dystrophic epidermolysis bullosa 9.8 CDKN2A TP53
42 squamous cell papilloma 9.8 CDKN2A TP53
43 pre-malignant neoplasm 9.8 CDKN2A TP53
44 juvenile pilocytic astrocytoma 9.8 CDKN2A TP53
45 barrett's adenocarcinoma 9.8 CDKN2A TP53
46 cervix carcinoma 9.8 CDKN2A TP53
47 gastrointestinal system benign neoplasm 9.7 CDKN2A TP53
48 skin squamous cell carcinoma 9.7 CDKN2A TP53
49 cellular schwannoma 9.7 CDKN2A TP53
50 cervix uteri carcinoma in situ 9.7 CDKN2A GP6 TP53

Graphical network of the top 20 diseases related to Anogenital Venereal Wart:



Diseases related to Anogenital Venereal Wart
Sources

Symptoms & Phenotypes for Anogenital Venereal Wart

About this section

Symptoms:

12
  • • anogenital warts

UMLS symptoms related to Anogenital Venereal Wart:


fever, pelvic pain, pruritus, penile warts

GenomeRNAi Phenotypes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased BBC3 mRNA expression GR00389-S-4 8.62 TCF7L1 TP53

MGI Mouse Phenotypes related to Anogenital Venereal Wart:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.76 AP3D1 CDKN2A GP6 IFNB1 TCF7L1 TLR7
2 integument MP:0010771 9.43 AP3D1 CDKN2A GP6 TCF7L1 TP53 UBE3A
3 no phenotypic analysis MP:0003012 9.02 CDKN2A IFNB1 TCF7L1 TP53 UBE3A
Sources

Drugs & Therapeutics for Anogenital Venereal Wart

About this section

Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
2
Zinc Approved, Investigational Phase 4 7440-66-6 23994
3 Liver Extracts Phase 4,Phase 3
4 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Micronutrients Phase 4
9 Trace Elements Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12
Catechin Nutraceutical Phase 4,Phase 1 154-23-4 9064
13
Epicatechin Investigational, Nutraceutical Phase 4,Phase 1 490-46-0 72276
14 Tea Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
15
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
16
Pancrelipase Approved, Investigational Phase 3 53608-75-6
17
Benzocaine Approved, Investigational Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
18 tannic acid Approved, Nutraceutical Phase 3,Not Applicable
19 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
20 Alkylating Agents Phase 3
21 Antineoplastic Agents, Alkylating Phase 3
22 Antirheumatic Agents Phase 3
23 pancreatin Phase 3
24
Nitric Oxide Approved Phase 2 10102-43-9 145068 160954
25
Digoxin Approved Phase 2 20830-75-5 30322 2724385
26
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
27
Coal tar Approved Phase 2 8007-45-2
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29 Ranpirnase Investigational Phase 1, Phase 2 196488-72-9
30 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 1, Phase 2,Phase 2
31 Anti-Infective Agents Phase 1, Phase 2,Phase 2,Not Applicable
32 Antiviral Agents Phase 1, Phase 2,Phase 2,Not Applicable
33 Protective Agents Phase 1, Phase 2,Phase 2,Not Applicable
34 Radiation-Protective Agents Phase 1, Phase 2,Phase 2
35 Pharmaceutical Solutions Phase 1, Phase 2,Not Applicable
36 Anti-Asthmatic Agents Phase 2
37 Anticoagulants Phase 2
38 Antioxidants Phase 2
39 Autonomic Agents Phase 2,Not Applicable
40 Bronchodilator Agents Phase 2
41 Calcium, Dietary Phase 2,Not Applicable
42 Chelating Agents Phase 2
43 Endothelium-Dependent Relaxing Factors Phase 2
44 Neurotransmitter Agents Phase 2,Not Applicable
45 Peripheral Nervous System Agents Phase 2,Not Applicable
46 Respiratory System Agents Phase 2
47 Vasodilator Agents Phase 2
48 Freund's Adjuvant Phase 2
49 Anti-Arrhythmia Agents Phase 2
50 diuretics Phase 2

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
2 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
3 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
4 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
5 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
6 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
7 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
8 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
9 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
10 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
11 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
12 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
13 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
14 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
15 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
16 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
17 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
18 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
19 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
20 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
21 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
22 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
23 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
24 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
25 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
26 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
27 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
28 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
29 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
30 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
31 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
32 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
33 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
34 Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Recruiting NCT03296397 Phase 3
35 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts Recruiting NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
36 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients Recruiting NCT03525210 Phase 3
37 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
38 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Recruiting NCT03546842 Phase 3
39 A Trial of X4P-001 in Patients With WHIM Syndrome Recruiting NCT03005327 Phase 2, Phase 3 X4P-001;Placebo
40 Safety and Tolerability Study of V501 in Japanese Boys (V501-200) Active, not recruiting NCT02576054 Phase 3
41 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Active, not recruiting NCT03158220 Phase 3
42 Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Not yet recruiting NCT03153566 Phase 3
43 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Not yet recruiting NCT02750202 Phase 3
44 Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
45 Recurrent and Nonrecurrent Condyloma Treatment Terminated NCT01639638 Phase 2, Phase 3 PROAPOPTOTIC PEPTIDE CIGB 300
46 Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine Unknown status NCT02710851 Phase 2
47 Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
48 Efficacy and Tolerability of Topical LFX453 for External Genital Warts Completed NCT02482428 Phase 2 Investigational Treatment;Aldara
49 Safety and Efficacy Study to Test Topical AS101 for External Genital Warts Completed NCT01555112 Phase 1, Phase 2 Topical AS101
50 Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts Completed NCT02849262 Phase 2 Omiganan (CLS001) topical gel;Vehicle topical gel

Search NIH Clinical Center for Anogenital Venereal Wart

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: condylomata acuminata

Sources

Genetic Tests for Anogenital Venereal Wart

About this section
Sources

Anatomical Context for Anogenital Venereal Wart

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Anogenital Venereal Wart:

19
Skin Of Vagina

MalaCards organs/tissues related to Anogenital Venereal Wart:

41
Skin, Cervix, Uterus, Testes, Liver, Kidney
Sources

Publications for Anogenital Venereal Wart

About this section

Articles related to Anogenital Venereal Wart:

(show all 26)
# Title Authors Year
1
Genital Warts, Lymphangioma, and Treatment with Imiquimod. ( 29803364 )
2018
2
Genital Warts, Lymphangioma, and Treatment with Imiquimod. ( 29803363 )
2018
3
Extramammary Paget's Disease Associated With Genital Wart and Lichen Sclerosus. ( 29202553 )
2017
4
Consensus of Clinical Practices And Associated Costs To Diagnose And Treat Genital Warts Caused By Human Papilloma Virus (Hpv) In Ecuador: Results From A Panel Of Experts. ( 26534450 )
2015
5
Human papilloma virus-infected genital warts in a girl with Costello syndrome. ( 25787333 )
2015
6
Angiokeratoma of vulva mimicking genital warts. ( 25404845 )
2014
7
Seborrheic keratosis of the vulva clinically mimicking a genital wart: a case study. ( 22171841 )
2013
8
Phylogenetically related, clinically different: human papillomaviruses 6 and 11 variants distribution in genital warts and in laryngeal papillomatosis. ( 24118667 )
2013
9
Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. ( 23820080 )
2013
10
Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. ( 21934446 )
2011
11
Extensive congenital vulvar lymphangioma mimicking genital warts. ( 20418997 )
2010
12
Multifocal penile syringoma masquerading as genital warts. ( 19438547 )
2009
13
A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients. ( 21938126 )
2009
14
New approaches to external genital warts and vulvar intraepithelial neoplasia. ( 18677144 )
2008
15
Role of human papilloma virus (HPV) in common and genital warts and its relation to P53 expression. ( 17496936 )
2006
16
Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. ( 12838415 )
2004
17
Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. ( 14616340 )
2003
18
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. ( 10858346 )
2000
19
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. ( 10480263 )
1999
20
A guide to immunotherapy of genital warts: focus on interferon and imiquimod. ( 18031142 )
1999
21
Drug treatment of common STDs: Part II. Vaginal infections, pelvic inflammatory disease and genital warts. ( 10537386 )
1999
22
Treatment of genital warts with an immune-response modifier (imiquimod). ( 9486679 )
1998
23
Genital warts, trichomoniasis and other concurrent STIs in Scotland. ( 9179657 )
1997
24
Recurrent respiratory papillomatosis with pulmonary cystic disease in a child, following maternal genital warts. ( 9155559 )
1997
25
Relation of p53 tumor suppressor protein expression to human papillomavirus (HPV) DNA and to cellular atypia in male genital warts and in premalignant lesions. ( 7653176 )
1995
26
The subtypes, distribution and location of human papillomavirus DNA in genital warts and genital Bowen's disease--a study using in situ DNA.DNA hybridization. ( 2561558 )
1989
Sources

Variations for Anogenital Venereal Wart

About this section
Sources

Expression for Anogenital Venereal Wart

About this section
Search GEO for disease gene expression data for Anogenital Venereal Wart.
Sources

Pathways for Anogenital Venereal Wart

About this section

Pathways related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.6 IFNB1 TCF7L1 TP53 UBE3A
2
Viral carcinogenesis 37
11.88 CDKN2A TP53 UBE3A
3
SMAD Signaling Network 64
11.58 CDKN2A TP53 UBE3A
4
DNA Damage Response (only ATM dependent) 1
11.19 CDKN2A TCF7L1 TP53
5
Gastric Cancer Network 2 1
10.98 ATAD2 TP53
6
Oncogene Induced Senescence 66
10.94 CDKN2A TP53
7
BARD1 signaling events 1
10.83 TOPBP1 TP53
8
Senescence and Autophagy in Cancer 1
10.82 CDKN2A IFNB1 TP53
9
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.6 CDKN2A TP53
10
TP53 Network 1
Show member pathways
 10.5 CDKN2A TP53
Sources

GO Terms for Anogenital Venereal Wart

About this section

Biological processes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.35 ATAD2 CDKN2A IFNB1 TP53 UBE3A
2 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53
Sources

Sources for Anogenital Venereal Wart

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....